Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.55 |
| ▸ | RARA | P10276 | 15/20 | 0.55 |
| ▸ | RARG | P13631 | 15/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075536 | 0.92 | RARB (0.53) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4507988 | 0.89 | RARB (0.49) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL8771704 | 0.88 | RARA (0.70) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6238262 | 0.82 | RARB (0.83) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6238257 | 0.82 | RARB (0.83) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL5328434 | 0.80 | RARB (0.56) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL5330571 | 0.78 | RARB (0.50) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6236775 | 0.78 | RARB (0.58) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6236767 | 0.78 | RARB (0.58) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6236772 | 0.78 | RARB (0.58) | RARBRARARARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265449-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-7166726-B2 | Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20030130515-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6538149-B1 | Skin disorders; anticarcinogenic and antiproliferative agents | ALLERGAN | 2003-03-25 | — | — | US | disclosed |
| CN-1102573-C | Aryl-or heteroaryl-substituted 3, 4-dihydroanthracenes and aryl-or heteroaryl-substituted benzo [1, 2-g ] -chromen-3-enes, benzo [1, 2-g ] -chromen-3-enes and benzo [1, 2-g ] -1, 2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN SALE CO (US) | 2003-03-05 | — | — | CN | disclosed |
| EP-0948478-B1 | ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6087505-A | Benzo[1,2-G]-chrom-3-ene, and benzo[1,2-G]-thiochrom-3-ene derivatives | ALLERGAN SALES, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| CN-1239941-A | Aryl or heteroaryl substd. 3, 4-dihydroanthracene and benzo [1,2-g]-chrom-3-ene, benzo [1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivs. | ALLERGAN SALE CO (US) | 1999-12-29 | — | — | CN | disclosed |
| EP-0948478-A1 | ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO 1,2-g]-CHROM-3-ENE, BENZO 1,2-g]-THIOCHROM-3-ENE AND BENZO 1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998025875-A1 | ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5728846-A | RETENOIDS, RETINOID ACTIVITY; AGONISTS, ANTAGONISTS | ALLERGAN (US) | 1998-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265449-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | RXRG, RARG, NR2E3 | RARB 6/4885RARA 7/4885RARG 2/4885 |
| US-20030130515-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | RXRG, NR2E3, RARG | RARB 7/4885RARA 8/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.